Advertisement
Canada markets open in 6 hours 17 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7271
    +0.0008 (+0.11%)
     

  • CRUDE OIL

    83.71
    +0.98 (+1.18%)
     

  • Bitcoin CAD

    89,034.62
    +4,807.79 (+5.71%)
     

  • CMC Crypto 200

    1,331.20
    +18.58 (+1.41%)
     

  • GOLD FUTURES

    2,405.10
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,426.50
    -120.75 (-0.69%)
     

  • VOLATILITY

    18.00
    0.00 (0.00%)
     

  • FTSE

    7,877.05
    0.00 (0.00%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference

Certara
Updated ·1 min read
Certara
Certara

PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.

Certara also announced that Company management will participate at the upcoming BofA Securities 2023 Healthcare Conference.

ADVERTISEMENT

Company management will present at 8:40AM PT on Wednesday, May 10th.

Live and archived webcasts of the events will be available on the “Investors” section of the Certara website at https://ir.certara.com/.

About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries. Visit us at www.certara.com.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com